Literature DB >> 2504483

Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.

B A Teicher1, D J Waxman, S A Holden, Y Y Wang, L Clarke, E Alvarez Sotomayor, S M Jones, E Frei.   

Abstract

The cytotoxicity of N,N',N''-triethylenethiophosphoramide (thiotepa) was studied in vitro in the MCF-7 human breast carcinoma cell line and in vivo using the EMT6 mouse mammary tumor model, under various conditions of oxygenation and in the presence and absence of Aroclor 1254-induced liver preparations. The cytotoxicity of thiotepa toward exponentially growing MCF-7 cells was markedly dependent on the presence of oxygen during the period of drug exposure, with 3 log greater cell kill at 500 microM thiotepa being observed when the cells were normally oxygenated compared with hypoxic cells. Incubation of thiotepa with an Aroclor 1254-induced rat liver S-9 homogenate, in the presence of a NADPH-regenerating system, resulted in an 8-fold increase in cytotoxicity towards the MCF-7 cells over a wide range of drug concentrations. Thiotepa was shown to be metabolized under these conditions in a NADPH- and O2-dependent reaction that was catalyzed by one or more microsomal cytochrome P-450 enzymes that were present in the S-9 fraction. The thiotepa metabolite triethylene phosphoramide, which hydrolyzes significantly faster than thiotepa, was significantly less cytotoxic toward the MCF-7 cells than was thiotepa itself, suggesting that it is unlikely to be the S-9 metabolite responsible for the observed increase in drug cytotoxicity. Moreover, triethylene phosphoramide cytotoxicity was only partially O2 dependent and was largely unaffected by incubation in the presence of the S-9 preparation, indicating a mechanism of action distinct from that of thiotepa. Tumor cell survival experiments with the EMT6 mouse mammary carcinoma system revealed that a 3.6-fold increase in thiotepa cytotoxicity was obtained by prior administration of the liver inducer Aroclor 1254 to the tumor-bearing animals, 5 days before drug treatment. Finally, the therapeutic effectiveness of thiotepa was significantly enhanced (3- to 5.8-fold increase in tumor growth delay) when an increase in oxygenation was achieved, by carbogen breathing, in animals given the perfluorochemical emulsion Fluosol-DA. These findings establish that the cytotoxic effects of thiotepa are oxygen dependent and may involve, at least in part, metabolic processes catalyzed by cytochrome P-450 enzymes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504483

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Authors:  A D Huitema; R A Mathôt; M M Tibben; J H Schellens; S Rodenhuis; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

2.  Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer.

Authors:  C Lewis; N Lawson; E M Rankin; G Morrison; A B MacLean; J Cordiner; J Cassidy; D J Kerr; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.

Authors:  B Hagen; O Dale; G Neverdal; S Azri; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.

Authors:  B A Teicher; S A Holden; G Ara; C S Ha; T S Herman; D Northey
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.

Authors:  B C Liang
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

6.  Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

7.  Reduced oxygenation in a rat mammary carcinoma after chemo- or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing.

Authors:  B A Teicher; E A Sotomayor; N P Dupuis; T Kusumoto; K Menon
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 8.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

9.  Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

Authors:  B A Teicher; S A Holden; N P Dupuis; Y Kakeji; M Ikebe; Y Emi; D Goff
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.